

A lifelong journey

Now indicated for use in children 2+



Starting early with AID in T1D.

ISPAD guidelines recommend early use of AID in children and adolescents living with T1D.¹


Supporting time in range through every stage of growth.

1 in 5

Children with T1D meet glycaemic targets in Australia.²

The LENNY³ trial evaluated the efficacy and safety of the MiniMed™ 780G in children aged 2 to 6 years with type 1 diabetes.

Study design: Open-label, multicentre, randomised, crossover trial. Key inclusion: ≥ 6 units of insulin daily.



Teenagers may not count every carb precisely.

With SmartGuard™,
they don't need to^{4,11}.



Simple size estimate is all that's needed.⁴



Small meal



Medium meal



Large meal

The Fix & Flex study compared simplified meal estimation versus precise carb counting in adolescents with type 1 diabetes on the MiniMed™ 780G.

6.8%

No significant difference in
HbA1c between groups.⁴

No severe hypoglycaemia
or DKA.⁴


30

grams of unannounced
carbohydrates, detected
and addressed automatically.⁵

Every site change is a disruption.

Up to **7 days**
between site changes

with stable and a skin-friendly patch that goes the distance comfortably.⁶



78.9%⁷

Average Time in Range in children ≤15 years in the real world with MiniMed™ 780G*

For Healthcare Professional Use Only. This material is intended solely for healthcare professionals and is not intended for distribution to, or use by, patients or the general public. Do not copy, reproduce, share, or redistribute this material without prior written authorization from MiniMed.

†Refers to Meal Detection™ technology, taking a bolus 15-20 mins before meal helps control *Real world data. 3,211 children. 24 countries. Recommended settings. When recommended settings of glucose target 5.5 mmol/L and AIT 2 hrs are used **Compared to multiple daily injections. ^Components sold separately.

References 1. Biester T, et al. Horm Res Paediatr. 2025;97:636-662. 2. Holmes-Walker DJ, et al. Intern Med J. 2023;53:61-67. 3. Battelino T, et al. Lancet Diabetes Endocrinol. 2025;13(8):662-673. 4. Petrovski G, et al. Diabetes Care. 2023;46(3):544-550. 5. Edd S, et al. Diabetes Obes Metab. 2026;28:61-68. 6. Zhang G, et al. J Diabetes Sci Technol. 2024;18(2):454-459. 7. Arrieta A, et al. Diabetes Obes Metab. 2022;24(7):1370-1379. Lower scores indicate better sleep quality. Please refer to the product insert or Instructions for Use for a complete list of indications, contraindications, warnings, precautions, and other important medical information. For further information, contact your local MiniMed™ representative.

Medtronic Australasia Pty Ltd. Level 8, 11 Khartoum Road, Macquarie Park, NSW 2113 Australia. Tel: +61 2 9857 9000, Toll Free: 1800 777 808. Email: australia.diabetes@medtronic.com. Approval AU-DBA-2600019. ©2026 Medtronic MiniMedInc. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc.™ Third-party brands are trademarks of their respective owners. All other brands are trademarks of a MiniMed company.

